Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

U. Kher · SciRah

Researcher profile · Semantic Scholar

U. Kher

Share profile

U. Kher — researcher profile on SciRah

h-index: 20
Works: 36
Citations: 3,939

Most-cited papers

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
K. Shitara, E. Van Cutsem, Y. Bang, C. Fuchs +24 more
2020JAMA Oncology1,034 citations Open access
Semantic Scholar
Combined modality therapy for primary CNS lymphoma.
L. DeAngelis, J. Yahalom, H. Thaler, U. Kher
1992Journal of Clinical Oncology537 citations
Semantic Scholar
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.
C. Chesnut, M. McClung, K. Ensrud, N. H. Bell +9 more
1995American Journal of Medicine375 citations
Semantic Scholar
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
J. Tucci, R. Tonino, R. Emkey, Christine A. Peverly +2 more
1996American Journal of Medicine224 citations
Semantic Scholar
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
M. Mateos, H. Blacklock, F. Schjesvold, A. Oriol +22 more
2019The Lancet Haematology220 citations Open access
Semantic Scholar
Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas
Dennis H. Kraus, S. Dubner, Louis B. Harrison, E. Strong +4 more
1994Cancer209 citations Open access
Semantic Scholar
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
S. Murphy, C. Cannon, M. Blazing, R. Giugliano +11 more
2016Journal of the American College of Cardiology204 citations Open access
Semantic Scholar
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
J. Paolini, Y. Mitchel, R. Reyes, U. Kher +7 more
2008American Journal of Cardiology176 citations
Semantic Scholar
Pediatric desmoid tumor: retrospective analysis of 63 cases.
Lawrence Faulkner, S. Hajdu, U. Kher, M. La Quaglia +3 more
1995Journal of Clinical Oncology166 citations
Semantic Scholar
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
J. Tabernero, E. Van Cutsem, Y. Bang, C. Fuchs +15 more
2019Journal of Clinical Oncology156 citations
Semantic Scholar
The importance of clinical staging of minor salivary gland carcinoma.
R. Spiro, H. Thaler, Wesley F. Hicks, U. Kher +2 more
1991American Journal of Surgery136 citations
Semantic Scholar
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
A. Gotto, C. Cannon, X. Li, S. Vaidya +8 more
2014American Journal of Cardiology92 citations
Semantic Scholar
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Z. Wainberg, C. Fuchs, J. Tabernero, K. Shitara +16 more
2021Clinical Cancer Research70 citations Open access
Semantic Scholar
Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study
A. Gotto, U. Kher, M. Chatterjee, Yang Liu +9 more
2014Journal of Cardiovascular Pharmacology and Therapeutics46 citations
Semantic Scholar
Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
S. L. Greenspan, S. Holland, L. Maitland-Ramsey, M. Poku +4 more
1996Proceedings of the Association of American Physicians46 citations
Semantic Scholar
KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
J. Tabernero, Y. Bang, C. Fuchs, A. Ohtsu +4 more
201641 citations
Semantic Scholar
Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062
K. Shitara, E. Van Cutsem, Y. Bang, C. Fuchs +15 more
2019Annals of Oncology29 citations Open access
Semantic Scholar
Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study.
J. Tabernero, E. Van Cutsem, Y. Bang, C. Fuchs +15 more
2019Annals of Oncology26 citations Open access
Semantic Scholar
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
E. Brinton, U. Kher, Sukrut Shah, C. Cannon +152 more
2015Journal of Clinical Lipidology26 citations
Semantic Scholar
A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
M. Mateos, H. Blacklock, F. Schjesvold, A. O. Rocafiguera +16 more
201824 citations
Semantic Scholar
Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
E. Van Cutsem, A. Valderrama, Y. Bang, C. Fuchs +10 more
2021ESMO Open22 citations Open access
Semantic Scholar
Nativity, complications, and pathology are determinants of surgical results for gastric cancer
Joseph G. Fortner, G. Lauwers, H. Thaler, R. Concepcion +3 more
1994Cancer21 citations Open access
Semantic Scholar
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.
Z. Wainberg, K. Shitara, E. Van Cutsem, L. Wyrwicz +16 more
2022Journal of Clinical Oncology20 citations Open access
Semantic Scholar
Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate/17β-estradiol and drospirenone/ethinyl estradiol on bleeding patterns in healthy women.
D. Mansour, C. Westhoff, U. Kher, T. Korver
2017Contraception20 citations
Semantic Scholar
The impact of measurement error on the comparison of two treatments using a responder analysis.
L. Oppenheimer, U. Kher
1999Statistics in Medicine17 citations
Semantic Scholar
Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.
Z. Wainberg, C. Fuchs, J. Tabernero, K. Shitara +16 more
202016 citations
Semantic Scholar
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
C. Ballantyne, Sukrut Shah, U. Kher, J. Hunter +5 more
2017American Journal of Cardiology14 citations Open access
Semantic Scholar
Effectiveness and safety of laropiprant on niacin-induced flushing.
D. Maccubbin, Fabian Chen, Jennifer W. Anderson, Waheeda Sirah +5 more
2012American Journal of Cardiology14 citations
Semantic Scholar
High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery.
L. Faulkner, K. Lindsley, U. Kher, G. Heller +2 more
1996Bone Marrow Transplantation12 citations
Semantic Scholar
Lack of Effect of Antacids on Single‐Dose Pharmacokinetics of Etoricoxib
Jules I. Schwartz, N. Agrawal, U. Kher, M. DeSmet +5 more
2007Journal of clinical pharmacology11 citations
Semantic Scholar
KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).
J. Shah, S. Jagannath, M. Mateos, A. Palumbo +3 more
201610 citations
Semantic Scholar
Tolbutamide inhibits gluconeogenesis in the tumor-influenced hepatocyte.
David Blumberg, Michael E. Burt, U. Kher, Murray F. Brennan
1993Journal of Surgical Research8 citations
Semantic Scholar
Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
E. Van Cutsem, A. Valderrama, Y. Bang, C. Fuchs +10 more
2019Annals of Oncology5 citations Open access
Semantic Scholar
Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
H. Chung, Y. Bang, J. Tabernero, E. Van Cutsem +14 more
2019Annals of Oncology4 citations Open access
Semantic Scholar
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients
M. Matsumoto, Kenshi Suzuki, J. Kuroda, M. Taniwaki +13 more
2021International journal of hematology3 citations
Semantic Scholar
Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
E. Ocio, J. Shah, S. Jagannath, M. Mateos +4 more
20162 citations Open access
Semantic Scholar
Bone turnover rate does not predict BMD response to alendronate
L. J. Hirsch, A. Santora, U. Kher, J. Yates +2 more
2006Osteoporosis International2 citations
Semantic Scholar
50TiPKEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
M. Mateos, H. Blacklock, A. O. Rocafiguera, S. Iida +6 more
20161 citations Open access
Semantic Scholar
Abstract 1634: Effects of the DP1-receptor Antagonist MK-0524 on Nicotinic Acid-Induced Flushing in Lipid Clinic Patients
J. Paolini, Y. Mitchel, R. Reyes, U. Kher +7 more
20061 citations
Semantic Scholar
EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL
A. Gotto, M. Chatterjee, Yang Liu, X. Li +10 more
20140 citations Open access
Semantic Scholar
Abstract 8824: Following Stable Therapy with Extended Release Niacin/Laropiprant, Continued Extended Release Niacin/Laropiprant Use Reduced Flushing versus Extended Release Niacin Alone in Dyslipidemic Patients
Fabian Chen, D. Maccubbin, Jennifer Weimer Anderson, Christine Mccrary Sisk +3 more
2011Circulation0 citations
Semantic Scholar
Response to alendronatie is independent of the baseline rate of bone turnover
L. J. Hirsch, D. Cumming, J. Dequeker, M. Favus +4 more
19950 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Van Cutsem×10
Invite
E. Van Cutsem — researcher profile on SciRah
Sukrut Shah×10
Invite
Sukrut Shah — researcher profile on SciRah
J. Tabernero×9
Invite
J. Tabernero — researcher profile on SciRah
K. Shitara×8
Invite
K. Shitara — researcher profile on SciRah

×8

Invite

Z. Wainberg — researcher profile on SciRah

Invite

Y. Mitchel — researcher profile on SciRah

Invite

Y. Bang — researcher profile on SciRah

Invite

C. Fuchs — researcher profile on SciRah

Invite

I. Kudaba — researcher profile on SciRah

M. Braghiroli×6

Invite

M. Braghiroli — researcher profile on SciRah

Invite

E. Goekkurt — researcher profile on SciRah

P. Marinello×6

Invite

P. Marinello — researcher profile on SciRah